MIV-323

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameMIV-323
Drug Alias Nameanti-RSV infection program (Medivir)anti-RSV infection program (Boehringer Ingelheim)MIV-323
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRespiratory syncytial virus F protein inhibitors
TargetsRespiratory syncytial virus F protein
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedivir AB
Active IndicationsN/A
Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeN/A
Related LinksN/A